

Special Issue

African Swine Fever Immunity and Vaccines

Message from the Guest Editor

Since its introduction into Georgia in 2007, African swine fever virus has spread across both Europe and Asia and has been responsible for the deaths of hundreds of millions of animals. Current control measures based on the rapid diagnosis, quarantine, and slaughter of affected animals have not been sufficient to prevent the disease from becoming established in different epidemiological situations across the globe. The main tools missing from the African swine fever control kit are vaccines suitable for preventing disease in both domestic and wild animals. Without such vaccines, it is difficult to envisage how the current epidemic can be brought under control and the disease, eradicated. Novel approaches are required, as, to date, inactivated viruses and attenuation through tissue culture passage have not yielded safe and effective vaccines. The causative agent is a complex pathogen with a complex immunopathology that is not well characterized. The mechanisms of protective immunity and protective antigens also remain to be fully described.

Guest Editor

Dr. Christopher Netherton

african Swine Fever Vaccinology Group, The Pirbright Institute, Surrey
GU24 0NF, UK

Deadline for manuscript submissions

closed (31 March 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/80447

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).